SynthesisWorld journal of surgical oncology2025
Efficacy and safety of secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aims to compare the efficacy and safety of secondary cytoreductive surgery (SCS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) versus SCS alone in the management of platinum-sensitive recurrent ovarian cancer (PSROC) through a systematic review and meta-analysis.
methodsA comprehensive search was performed in the PubMed, EMBASE, Web of Science, and Cochrane Library databases through December 31, 2024. Studies were eligible if they compared outcomes between individuals receiving SCS combined with HIPEC and those receiving SCS alone. The primary outcomes included progression-free survival (PFS) and overall survival (OS), measured using hazard ratios (HRs) with 95% confidence intervals (CIs). Secondary outcomes included the incidence of complications, reported as relative risks (RRs) with 95% CIs. Statistical analyses were conducted using Stata software (version 15.1).
resultsA total of seven studies comprising 1,136 patients were included. Of these, 563 patients underwent SCS combined with HIPEC, while 573 received SCS alone. The pooled analysis indicated that the addition of HIPEC to SCS was associated with a significant improvement in OS (HR = 0.76, 95% CI [0.62, 0.94], p = 0.01). However, no statistically significant improvement was observed in PFS (HR = 0.91, 95% CI [0.72, 1.15], p = 0.43). The overall incidence of grade ≥ 3 complications did not differ significantly between the two groups (RR = 1.42, 95% CI [1.00, 2.01], p = 0.05). Nonetheless, the incidence of nephrotoxicity (RR = 1.71, 95% CI [1.20, 2.43]) and anemia (RR = 1.38, 95% CI [1.18, 1.62]) was higher in the group treated with SCS and HIPEC. No significant difference was noted in the incidence of thrombocytopenia (RR = 1.41, 95% CI [0.76, 2.59]).
conclusionThe integration of HIPEC with SCS may improve OS among patients with PSROC without a marked increase in severe complications; however, increased risks of nephrotoxicity and anemia should be considered in clinical decision-making. Further standardization of HIPEC protocols and the implementation of large-scale randomized controlled trials are recommended to confirm these findings and establish definitive clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.